Results 151 to 160 of about 15,932 (195)

Effect of dapagliflozin on heart failure with reduced ejection fraction in children. [PDF]

Front Cardiovasc Med
Lin S, Chen Y, Zhu D, Wu J, Fu L, Li F, Guo X.   +6 more
europepmc   +1 more source

Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysis. [PDF]

Ren Fail
Irvania AN, Tsauri GAA, Yantisetiasti A, Sofiatin Y.   +3 more
europepmc   +1 more source

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Med (Lausanne)
Yin M, Tan H, Xie S, Kuang Y, Wu Q, Ma J, Guo C.   +6 more
europepmc   +1 more source

Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement. [PDF]

Biol Direct
Li A, Ye Y, Tang J, Hu J, Shi M, Wu Y, Ji C, Zhang H.   +7 more
europepmc   +1 more source

Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized Trial. [PDF]

J Clin Med
Ortega-Paz L, Laudani C, Morr CI, Sionis A, Vidal-Cales P, Arevalos V, Andrea R, De Diego O, Ortega E, Jimenez-Trinidad FR, Dantas AP, Angiolillo DJ, Sabaté M, Ortiz-Pérez JT, Brugaletta S.   +14 more
europepmc   +1 more source

Correction: Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. [PDF]

Cell Biosci
Tsai KL, Hsieh PL, Chou WC, Cheng HC, Huang YT, Chan SH.   +5 more
europepmc   +1 more source

Diabetes and hyperglucosuria exacerbate the severity of urinary tract infection caused by uropathogenic <i>E</i>. <i>coli</i> in the mouse model. [PDF]

Infect Immun
Neupane S, George I, Vanitshavit V, Hejtmancik T, Kim DM, Wright G, Adams LG, Subashchandrabose S.   +7 more
europepmc   +1 more source

Dapagliflozin Protects Cardiomyocytes against Doxorubicin-Induced Toxicity by Modulating Sirtuin 1/Sirtuin 3 and Ferroptosis Pathway. [PDF]

ACS Pharmacol Transl Sci
Khine HEE, Mangmool S, Parichatikanond W.   +2 more
europepmc   +1 more source

Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study. [PDF]

Cureus
Chawla R, T K S, Singh KP, Mehta A, Chattopadhyay M, Rakshit KM, Motiramani N, Philip R, Shinde AC, K SM, Revenkar S, Patel K.   +11 more
europepmc   +1 more source

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Gao S, Zhang F, Xie X, Fan L.
europepmc   +1 more source